8 Unstoppable Stocks That Could Make You Richer

6. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Average Analysts Upside Potential as of October 25: 46.78%

Year-to-date gains: 38.10%

Number of Hedge Fund Holders: 55

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology company that discovers and develops RNA-targeted therapeutics and gene therapies for treating rare diseases. It is one of the unstoppable stocks that could make you richer as it achieves significant milestones in the gene therapy space. The U.S. Food and Drug Administration (FDA) recently expanded the approval of Elevidys, the company’s flagship product, making Sarepta a significant player in the Duchenne muscular dystrophy DMD treatment market.

Elevidys has shown statistically significant effects on secondary endpoints that reflect muscle function in clinical trials, filling a crucial gap in treating DMD. Amid the approval and strong demand, Elevidys’ peak sales in the U.S. market alone are expected to range from $2.7 billion to over $5 billion per year.

Since its approval in June 2023, the therapy has generated $334 million in revenue, with sales of $134 million in the first quarter of 2024. There is now a straightforward way for those sales to keep increasing for even longer. In the upcoming years, it is anticipated that the treatment’s effectiveness and Sarepta’s experience with commercialization will spur quick adoption and revenue growth.

Elevidys’s broader approval has greatly improved Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s financial prospects. Revenue totalled $1.2 billion last year, but the company lost $536 million on that. Elevidys’ revenue contribution was $200 million. Thanks to the label expansion, Sarepta will have a far better chance of making money in the future.

While Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is already up by more than 30% for the year, analysts on Wall Street remain optimistic about its long-term prospects, with an average price target of $195.20, implying 46.78% upside potential as of October 25 2024.

As of Q2 2024, 55 hedge funds tracked by Insider Monkey held positions in Sarepta Therapeutics, Inc. (NASDAQ:SRPT), with stakes totaling $2.90 billion. VenBio Select Advisor holds the largest stake, valued at $474 million.